MiniMed Flex Is FDA Cleared: Smallest Pump, Phone-Run
MiniMed Flex Is FDA Cleared — Smaller, Screenless, and Run From Your Phone
MiniMed's smallest insulin pump ever just got the FDA's green light: about half the size of the 780G, controlled entirely by smartphone, and powered by the SmartGuard algorithm with meal detection. Here's what's in it, who it's for, and what to know before you decide anything.
Posted June 2026 · Juicebox Podcast BlogThe pump-size race is officially on, and MiniMed just made its move. On March 18, MiniMed announced FDA clearance of the MiniMed Flex — a next-generation insulin pump that's roughly half the size of the MiniMed 780G, about the size of two stacked insulin vials, and the company's first pump with no screen at all. Everything runs through an app on your phone, iOS or Android, at launch.
If you follow this space, you know what that means: every major pump company is now converging on the same idea — small, discreet, phone-controlled hardware with the algorithm doing the heavy lifting in the background. Tandem went there with the Mobi. Omnipod has owned tubeless-and-small for years. Now MiniMed has its own answer, and it arrives with a detail worth pausing on: this is MiniMed's first FDA clearance as a standalone, publicly traded company — announced just one week after its IPO and separation from Medtronic. They wanted to come out swinging, and this is the swing.
What's actually in the box
Under the new shell, the Flex runs the same engine MiniMed users already know: the SmartGuard algorithm with Meal Detection technology, which automatically adjusts basal and delivers autocorrections in real time. The company points to real-world results of 80% Time in Range with recommended settings — with the usual real-world-data caveats attached, which is fair.
The hardware story is where things get interesting. Despite shrinking the pump by about half, MiniMed kept a full 300-unit reservoir — meaningful if you have higher insulin needs and have ever felt squeezed by smaller-capacity options. It stays compatible with MiniMed's existing infusion set lineup, including the Extended infusion set with up to seven days of wear, which the company says can mean up to 96% fewer injections compared with traditional insulin therapy.
And here's the line that made me sit up: at commercial launch, the Flex will support MiniMed's newest sensor portfolio — the Simplera Sync sensor and the Instinct sensor, which is made by Abbott. For a company that historically kept its ecosystem closed to its own sensors, offering an Abbott-built option is a genuine shift. Sensor choice has been one of the biggest reasons people ruled MiniMed in or out. That calculus just changed.
The Forward Program: don't miss this if you're deciding now
MiniMed also announced the MiniMed Forward Program: people who start on the 780G now can upgrade to the Flex for $0 when it ships. Per the fine print, that applies to customers who purchased a 780G between February 18, 2026 and launch. If you're mid-decision on a pump right now, that program is the practical headline of this whole announcement — it removes the “should I wait?” penalty.
On timing: the rollout starts with a customer experience phase this spring for select current MiniMed customers, with a broader commercial launch planned for the summer. The clearance covers people ages 7 and up with type 1 diabetes, and adults 18 and up with insulin-requiring type 2 diabetes.
Roughly two stacked insulin vials. Worn in a pocket or out of sight, controlled entirely from a compatible smartphone app on iOS or Android.
The same adaptive system MiniMed users know, auto-adjusting and autocorrecting in real time, with real-world reports of 80% Time in Range at recommended settings.
At launch, the Flex supports Simplera Sync and the Abbott-built Instinct sensor — a real opening of what's been a closed sensor ecosystem.
Eligible 780G purchasers (Feb 18, 2026 through launch) can move to the Flex for free when it becomes commercially available.
My take: smaller pumps don't shrink the job
I'm genuinely glad to see this. Competition on form factor is good for everyone — it drags the whole industry toward devices people actually want to wear. A screenless, phone-controlled pump with a 300-unit tank and a seven-day set is a real quality-of-life proposition, especially for teens, athletes, and anyone who's tired of clipping a brick to their waistband.
But here's the thing I'll keep saying no matter whose logo is on the pump: the algorithm is only as good as the settings and the understanding underneath it. Meal detection is a safety net, not a substitute for bolusing well. A smaller pump doesn't change how insulin works — timing and amount are still the entire game. If you hand any automated system bad settings and no pre-bolus, it will faithfully automate mediocre results. Get the foundation right and these systems genuinely shine.
Thinking about switching?
This is news, not a recommendation. Pump choice is personal — sensor preference, insurance coverage, insulin needs, tubed vs. tubeless, and how you feel about phone-only control all matter. Talk it through with your endocrinologist, and if you're buying a 780G in the meantime, ask about Forward Program enrollment so you don't leave the free upgrade on the table.
Want to learn more about MiniMed and the Flex? Use my link — bit.ly/3TQI7Gh — it takes you to MiniMed and lets them know the Juicebox Podcast sent you.
New pump, same fundamentals. Learn the part the device can't do.
The Juicebox Podcast has hundreds of conversations about pumps, algorithms, settings, and getting more out of automated insulin delivery — searchable by your exact question.
MiniMed Episodes Learn More at MiniMedRead the full disclaimer
